MNMD241115P13000
- 0.00
- 0.000.00%
Mind Medicine Newsroom
Express News | Mind Medicine Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
Mind Medicine's Strategic Advancements and Clinical Progress Drive Buy Rating
CCORF Maintains Mind Medicine(MNMD.US) With Buy Rating, Raises Target Price to $16
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Cuts Target Price to $21
RBC Capital Keeps Their Buy Rating on Mind Medicine (MNMD)
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)
Express News | Mind Medicine (MindMed) Inc : RBC Raises Target Price to $21 From $20
Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript Summary
Mind Medicine's Financial Health and Phase 3 Progress
10-Q: Quarterly report
Mind Medicine Q3 2024 GAAP EPS $(0.27) Beats $(0.28) Estimate
Mind Medicine GAAP EPS of -$0.27 Beats by $0.03
Express News | MindMed Q3 Net Income USD -13.684 Million
Massachusetts Psychedelics Legalization Initiative Poised to Fail
Massachusetts may be the next stop for legalization, is it a good investment opportunity for psychedelic drug concept stocks?
On Tuesday, Massachusetts voters will decide whether the state will legalize psilocybin, a psychedelic compound found in "magic mushrooms", worth paying attention to related concept stocks.
Legalizing Psychedelics: Is Massachusetts Next?
Earnings Preview: MNMD to Report Financial Results Post-market on November 07
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
FDA Is Said to See "Path Forward" for Ecstasy-based Drug
Bright Minds Rally Ends as Psychedelic Stocks Extend Volatility